Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 616 of 5804
-
Could a single cell infusion help newly diagnosed type 1 diabetes patients?
Disease control Recruiting nowThe brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
Phase: PHASE1, PHASE2 • Sponsor: Creative Medical Technology Holdings Inc • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug shows promise for Hard-to-Treat throat cancer
Disease control OngoingThe objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
Phase: PHASE2 • Sponsor: Shanghai Miracogen Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug aims to shield kidneys during heart surgery
Disease control TerminatedThe primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New brain zapping method aims to lift depression in just 5 days
Symptom relief OngoingThe goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I at the end of the treatment Participants will re…
Sponsor: Magnus Medical • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo aims to boost immune attack on lung cancer
Disease control Recruiting nowThis phase II trial tests whether CXCR1/2 inhibitor SX-682 (SX-682) with pembrolizumab works to treat patients with stage IIIC or IV non-small cell lung cancer that has spread to other parts of the body (metastatic) or that has come back (recurrent). SX-682 is a drug that binds t…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New stroke drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke
Phase: PHASE2 • Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThe goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma. The names of the treatment interventions involved in this study are:…
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug shows promise for Sjogren's sufferers in major trial
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of subcutaneous Telitacicept versus placebo in subjects with active primary Sjogren's Syndrome.
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could a stronger starting dose of buprenorphine get more people into opioid addiction treatment?
Disease control Recruiting nowThis project, involving two distinct clinical trials, tests whether induction to a higher than currently recommended buprenorphine (BUP) induction dose is safe and can improve the proportion of patients who engage in comprehensive addiction services within 7-day of induction. Tr…
Phase: PHASE3 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for kids with severe asthma: drug aims to cut attacks
Disease control OngoingA study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticost…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill could ease stiff back pain for thousands
Disease control OngoingThis study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) and is safe to use. The study will also be comparing 200 mg with 100 mg filgotinib a day to see if the lower dose also helps to treat…
Phase: PHASE3 • Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New mRNA vaccine aims to shield transplant patients from dangerous virus
⭐️ VACCINE ⭐️ OngoingThe main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 p…
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:35 UTC
-
Moderna launches first human test of mRNA vaccine against Epstein-Barr virus
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:52 UTC
-
Needle-Free hope: new shot delivery may ease myeloma treatment
Disease control OngoingThe main purpose of this study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior lines of therapy, and to characterize the PK of is…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Belly fat graft could outsmart brain Cancer's defenses
Disease control Recruiting nowThis single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
Phase: NA • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Magnesium shield: could a simple mineral prevent Chemo-Induced kidney failure?
Prevention Recruiting nowIn this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 07:59 UTC
-
Could a sweetener stop deadly infections in transplant kids?
Disease control OngoingBloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT). Unfortunately, there are currently no known strategies to prevent these BSI in this …
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for FSHD: experimental drug AOC 1020 completes early testing
Disease control CompletedA Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New combo shot helps east asians shed pounds in major trial
Disease control CompletedThis study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in th…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New daily pill could rival insulin for diabetes and heart risk
Disease control CompletedThe main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC